Engineered immune cells take aim at deadly brain tumors
Disease control
Terminated
This early-phase trial is testing a new treatment called CHM-1101 for people with a type of brain cancer (glioblastoma) that has come back or is getting worse. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack tumor cells. The …
Phase: PHASE1 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC